A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
167/192
A61K 31/565 (2006.01) A61K 31/57 (2006.01)
Patent
CA 1198057
ABSTRACT OF THE DISCLOSURE A method of contraception and a pharmaceutical package for effecting the method are disclosed. The method comprises a three phase sequence of estrogen/- progestogen administration which is a daily sequence of unit dosaqes over a repeating cycle, which dosage sequence comprises, for one cycle: (a) administering, as phase one, for a period of 5-8 days, daily dosages of a combination of an estrogen and a progestogen, wherein the amounts of estrogen and progestogen correspond in estrogenic activity to about 20-40 9 of ethinyl estradriol, and in progestogenic activity to about 0.3-0.8 mg of norethindrone, followed by; (b) administering, as phase two, for a period of 7-11 days, a combination of an estrogen and a progestogen in daily dosages wherein the estrogen daily dosage is the same as that administered in phase one and the progestogen daily dosage is twice that administered in phase one, followed by; (c) administering, as phase three, for a period of 3-7 days, a combination of an estrogen and a progestogen in daily dosages the same as those administered in phase one, followed by; (d) administering, as phase four, no therapeutically active dosage, i.e. either no treatment or a placebo each day for 6-8 days, with the proviso that the total number of days in phases one through three is 21.
409011
Johnson Douglas S. Q.c.
Syntex (u.s.a.) Llc.
LandOfFree
Method of contraception using peak progestogen dosage does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of contraception using peak progestogen dosage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of contraception using peak progestogen dosage will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1318216